Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Inventory (2016 - 2025)

Historic Inventory for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $176.5 million.

  • United Therapeutics' Inventory rose 2031.36% to $176.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.5 million, marking a year-over-year increase of 2031.36%. This contributed to the annual value of $157.9 million for FY2024, which is 4123.43% up from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Inventory is $176.5 million, which was up 2031.36% from $169.2 million recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Inventory peaked at $176.5 million during Q3 2025, and registered a low of $88.2 million during Q1 2022.
  • Its 5-year average for Inventory is $117.8 million, with a median of $103.3 million in 2023.
  • As far as peak fluctuations go, United Therapeutics' Inventory plummeted by 589.45% in 2022, and later skyrocketed by 4123.43% in 2024.
  • Over the past 5 years, United Therapeutics' Inventory (Quarter) stood at $93.8 million in 2021, then increased by 8.74% to $102.0 million in 2022, then grew by 9.61% to $111.8 million in 2023, then soared by 41.23% to $157.9 million in 2024, then grew by 11.78% to $176.5 million in 2025.
  • Its Inventory stands at $176.5 million for Q3 2025, versus $169.2 million for Q2 2025 and $165.4 million for Q1 2025.